β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.

作者: Arturo D Mancini , Gyslaine Bertrand , Kevin Vivot , Éric Carpentier , Caroline Tremblay

DOI: 10.1074/JBC.M115.644450

关键词: Free fatty acid receptor 1Signal transductionHeterotrimeric G proteinCell signalingBeta-ArrestinsArrestinCell biologyFunctional selectivityBiologyG proteinEndocrinologyInternal medicine

摘要: FFAR1/GPR40 is a seven-transmembrane domain receptor (7TMR) expressed in pancreatic β cells and activated by FFAs. Pharmacological activation of GPR40 strategy under consideration to increase insulin secretion type 2 diabetes. known signal predominantly via the heterotrimeric G proteins Gq/11. However, 7TMRs can also activate functionally distinct protein-independent signaling β-arrestins. Further, protein- β-arrestin-based be differentially modulated different ligands, thus eliciting ligand-specific responses ("biased agonism"). Whether engages β-arrestin-dependent mechanisms subject biased agonism unknown. Using bioluminescence resonance energy transfer-based biosensors for real-time monitoring cell living cells, we detected ligand-induced GPR40-β-arrestin interaction, with synthetic agonist TAK-875 being more effective than palmitate or oleate recruiting β-arrestins 1 2. Conversely, acted as partial Gq/11-dependent relative both blockade Gq activity decreased FFA-induced secretion. In contrast, knockdown genetic ablation β-arrestin an insulin-secreting line mouse islets, respectively, uniquely attenuated insulinotropic TAK-875, providing functional validation biosensor data. Collectively, these data reveal that addition coupling Gq/11, linked 2-mediated axis. These observations expose previously unrecognized complexity transduction may guide development agonists showing improved clinical profile

参考文章(41)
Chi Shing Sum, Irina G. Tikhonova, Susanne Neumann, Stanislav Engel, Bruce M. Raaka, Stefano Costanzi, Marvin C. Gershengorn, Identification of Residues Important for Agonist Recognition and Activation in GPR40 Journal of Biological Chemistry. ,vol. 282, pp. 29248- 29255 ,(2007) , 10.1074/JBC.M705077200
James W Wisler, Kunhong Xiao, Alex RB Thomsen, Robert J Lefkowitz, Recent developments in biased agonism. Current Opinion in Cell Biology. ,vol. 27, pp. 18- 24 ,(2014) , 10.1016/J.CEB.2013.10.008
Chiori Yabuki, Hidetoshi Komatsu, Yoshiyuki Tsujihata, Risa Maeda, Ryo Ito, Kae Matsuda-Nagasumi, Kensuke Sakuma, Kazumasa Miyawaki, Naoya Kikuchi, Koji Takeuchi, Yugo Habata, Masaaki Mori, A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 PLOS ONE. ,vol. 8, ,(2013) , 10.1371/JOURNAL.PONE.0076280
Ankita Srivastava, Jason Yano, Yoshihiko Hirozane, Georgia Kefala, Franz Gruswitz, Gyorgy Snell, Weston Lane, Anthony Ivetac, Kathleen Aertgeerts, Jasmine Nguyen, Andy Jennings, Kengo Okada, High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 Nature. ,vol. 513, pp. 124- 127 ,(2014) , 10.1038/NATURE13494
K. C. Kong, A. J. Butcher, P. McWilliams, D. Jones, J. Wess, F. F. Hamdan, T. Werry, E. M. Rosethorne, S. J. Charlton, S. E. Munson, H. A. Cragg, A. D. Smart, A. B. Tobin, M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 21181- 21186 ,(2010) , 10.1073/PNAS.1011651107
Céline Galés, Joost J J Van Durm, Stéphane Schaak, Stéphanie Pontier, Yann Percherancier, Martin Audet, Hervé Paris, Michel Bouvier, Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes Nature Structural & Molecular Biology. ,vol. 13, pp. 778- 786 ,(2006) , 10.1038/NSMB1134
Jonathan B Houze, Liusheng Zhu, Ying Sun, Michelle Akerman, Wei Qiu, Alex J Zhang, Rajiv Sharma, Michael Schmitt, Yingcai Wang, Jiwen Liu, Jinqian Liu, Julio C Medina, Jeff D Reagan, Jian Luo, George Tonn, Jane Zhang, Jenny Ying-Lin Lu, Michael Chen, Edwin Lopez, Kathy Nguyen, Li Yang, Liang Tang, Hui Tian, Steven J Shuttleworth, Daniel C-H Lin, None, AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorganic & Medicinal Chemistry Letters. ,vol. 22, pp. 1267- 1270 ,(2012) , 10.1016/J.BMCL.2011.10.118
Maria Hauge, Marie A. Vestmar, Anna S. Husted, Jeppe P. Ekberg, Michael J. Wright, Jerry Di Salvo, Adam B. Weinglass, Maja S. Engelstoft, Andreas N. Madsen, Michael Lückmann, Michael W. Miller, Maria E. Trujillo, Thomas M. Frimurer, Birgitte Holst, Andrew D. Howard, Thue W. Schwartz, GPR40 (FFAR1) – Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo Molecular metabolism. ,vol. 4, pp. 3- 14 ,(2015) , 10.1016/J.MOLMET.2014.10.002
A. D. Mancini, V. Poitout, GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Diabetes, Obesity and Metabolism. ,vol. 17, pp. 622- 629 ,(2015) , 10.1111/DOM.12442
Jing Qian, Chun Wu, Xiaopan Chen, Xiangmei Li, Guoyuan Ying, Lili Jin, Qiang Ma, Guo Li, Ying Shi, Guozheng Zhang, Naiming Zhou, Differential requirements of arrestin-3 and clathrin for ligand-dependent and -independent internalization of human G protein-coupled receptor 40 ☆ Cellular Signalling. ,vol. 26, pp. 2412- 2423 ,(2014) , 10.1016/J.CELLSIG.2014.07.019